What's right (and wrong) with racially stratified research and therapies

Journal of the National Medical Association

Volumn 99, Issue 6, 2007, Pages 693-696

  Sade, Robert M ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Ace inhibitors; Race ethnicity

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE;

DRUG APPROVAL; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; REVIEW; SOCIOECONOMICS;

AFRICAN AMERICANS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CONTINENTAL POPULATION GROUPS; DRUG APPROVAL; DRUG COMBINATIONS; DRUG INDUSTRY; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; PREJUDICE; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VARIATION (GENETICS);

EID: 34347325238     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Meadows M. FDA Approves Heart Drug for Black Patients. FDA Consumer Magazine. 2005;39(5):8-9.
2. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314(24):1547-1552.
3. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303-310.
4. Bloche MG. Race-based therapeutics. N Engl J Med. 2004:351(20):2035-2037.
5. Carson P, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5(3):178-187.
6. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-2057.
7. Stein R. FDA approves controversial heart medication for blacks. Washington Post. 2005;June 24:A15.
8. NitroMed Inc. FDA approves BiDil for treatment of heart failure drug for black patients. June 23, 2005. www.nitromed.com/pdf/Approval%20Press%20Release. pdf#search= %22FDA%20Approves%20BiDil%20For%20Treatment%20of%20Heart%20Failure%20 Drug%20for%20Black%20Patients%22. Accessed 09/18/06.
9. Schwartz RS. Racial profiling in medical research. N Engl J Med. 2001;344(18):1392-1393.
10. Wood AJ. Racial differences in the response to drugs - pointers to genetic differences. N Engl J Med. 2001;344(18):1394-1396.
11. Chepesiuk R, Jones J. Are race-specific drugs unethical? With BiDil on the market, experts weigh the moral implications. Black Enterprise. November 2005. www.findarticles.com/p/articles/mi_m1365/is_4_36/ai_n15890897. Accessed 09/18/06.
12. Moran AE, Cooper RS. Isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2005;352:(10):1041-1043.
13. A bitter pill for black hearts. The Black Commentator, 2005. www.alternet.org/story/23185/. Accessed 03/23/06.
14. Friedman M. The social responsibility of business is to increase its profits. The New York Times Magazine. September 13, 1970.
15. Sternberg E. The universal principles of business ethics. In: Business Ethics in the Global Market. Stanford: Hoover Institution Press; 1999:1-36.
16. Sade RM. Medicine and managed care, morals and markets. In: Bondeson J, Jones J, eds. The Ethics of Managed Care: Professional Integrity and Patient Rights. Boston, MA: Kluwer Academic Publishers; 2003:55-74.